Who Paid My Doc
Daniel Barba
Orthopaedic Surgery of the Spine Escondido, CA Medical Doctor
NPI 1407128580 CMS profile 244728
355 E Grand Ave Ste 1, Escondido, CA 92025
General payments
$1,482,323
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Daniel Barba of Escondido, CA is reported in the CMS Open Payments database as having received $1,482,323 across 464 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 96th percentile of Orthopaedic Surgery of the Spine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $307,416 | 86 | |
| 2024 | General | $273,462 | 80 | |
| 2023 | General | $231,448 | 86 | |
| 2022 | General | $216,957 | 67 | |
| 2021 | General | $188,269 | 52 | |
| 2020 | General | $128,282 | 34 | |
| 2019 | General | $136,488 | 59 |
Beside peers
- Daniel Barba
- Orthopaedic Surgery of the Spine median
- Middle half of Orthopaedic Surgery of the Spine
- National median
In program year 2025, general payments to Daniel Barba were reported at $307,416. Among 1,704 Orthopaedic Surgery of the Spine profiles paid that year, the median was $2,061 and the middle half received between $347 and $14,651.
Show as a table
| Year | Daniel Barba | Orthopaedic Surgery of the Spine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $136,488 | $2,106 | $337–$18,608 | $163 |
| 2020 | $128,282 | $1,213 | $156–$15,082 | $114 |
| 2021 | $188,269 | $1,834 | $271–$15,617 | $132 |
| 2022 | $216,957 | $2,015 | $320–$17,036 | $149 |
| 2023 | $231,448 | $1,925 | $336–$14,599 | $160 |
| 2024 | $273,462 | $2,110 | $341–$12,483 | $164 |
| 2025 | $307,416 | $2,061 | $347–$14,651 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 11 drugsPart D claims
749
Drug cost
$7,413
Branded share of claims
28.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gabapentin | Generic | 277 | $2,640 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 157 | $1,961 | |
| Tramadol Hcl | Generic | 132 | $662 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 47 | $644 | |
| Celecoxib | Generic | 23 | $608 | |
| Methylprednisolone | Generic | 41 | $329 | |
| Cyclobenzaprine Hcl | Generic | 16 | $169 | |
| Ibuprofen | Generic | 12 | $142 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 11 | $121 | |
| Meloxicam | Generic | 18 | $113 |
The 10 drugs with the highest cost, of 11 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 41 billing codesPaid by Medicare
$299,715
Medicare patients
665
Services billed
17,949
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 27% | |
| Depression | 27% | |
| Osteoporosis | 24% | |
| Ischemic heart disease | 21% | |
| Chronic kidney disease | 21% | |
| Atrial fibrillation | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 155 | 15,331 | $1,510 |
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 97 | 280 | $1,199 |
| Injection, methylprednisolone acetate, 80 mg J1040 | Office | 22 | 22 | $146 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
464 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Orthopaedic Surgery of the Spine in California
Hyun Bae
Orthopaedic Surgery of the Spine · Santa Monica, CA
Choll Kim
Orthopaedic Surgery of the Spine · San Diego, CA
Stacey Bederman
Orthopaedic Surgery of the Spine · Orange, CA
Gregory Mundis
Orthopaedic Surgery of the Spine · La Jolla, CA
Paul Slosar
Orthopaedic Surgery of the Spine · Daly City, CA
Babak Barcohana
Orthopaedic Surgery of the Spine · Van Nuys, CA
Related records
Orthopaedic Surgery of the Spine in California
Practitioners in the same specialty and state, ranked by reported value.
All Orthopaedic Surgery of the Spine
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.